Aptabridge - Crunchbase Company Profile & Funding

Q: Where is Aptabridge's headquarters?

Aptabridge is located in Baltimore, Maryland, United States.

Q: When was the last funding round for Aptabridge?

Aptabridge closed its last funding round on obfuscated from a Grant round.

Q: How much funding has Aptabridge raised to date?

Aptabridge has raised obfuscated.

Overview

Aptabridge

Total Funding

obfuscation

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Aptabridge

Aptabridge is a next-generation drug design platform to leverage DNA nanoparticles for immunotherapy.

Closed

Founded

obfuscation

Private

Grant

Baltimore, Maryland, United States

1-10

aptabridge.com/

Biotechnology

Health Care

Funding Rounds

Grant

OBF

obfuscation

Key People

Julie Clauss: Founder & Board member

Details

Legal Name

Aptabridge Therapeutics, Inc.

Operating Status

Closed

Company Type

For Profit

Founders

Julie Clauss

About the Company

Aptabridge is a next-generation drug design platform to leverage DNA nanoparticles for immunotherapy.

Diversity Spotlight

Women Founded

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

Next Generation Drug Design Platform

A platform leveraging DNA nanoparticles for immunotherapy, designed to treat complex diseases by engaging two disease targets with one molecule.

DNA Nanoparticles for Immunotherapy

Uses DNA nanoparticles to overcome challenges faced by bispecific antibodies, aiming for safer, lower cost, and easier manufacturing.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant
obfuscated obfuscation	Grant - Aptabridge	—	obfuscated obfuscation	—	Grant